Proactive Investors - Run By Investors For Investors

Summit identifies possible new ways to treat hospital-acquired superbugs

Using its Discuva platform, Summit has identified genes which are essential for pathogens like MRSA to survive, information which it will use to try to develop new drug candidates
pathogen
Superbugs are growing increasingly resistant to existing antibiotics

Summit Therapeutics PLC (LON:SUMM) reckons it might have found “multiple” new ways to attack and kill hospital-acquired superbugs such as MRSA.

New treatments for the ESKAPE – Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. – pathogens are needed as they become increasingly resistant to existing antibiotics.

WATCH: Summit Therapeutics sees a bright future for its antibiotics programmes

Using its Discuva platform, Summit said it had identified genes which are essential for these pathogens to survive, information which it will use to try to develop new drug candidates.

Several of these targets are now the focus of Summit’s drug development programmes, with the platform having already discovered potential new mechanism antibiotics against them.

“At the core of our innovation is our powerful Discuva Platform,” said chief executive Glyn Edwards.

“The platform allows us to uncover possible new ways to combat the potentially deadly ESKAPE pathogens.

“We can then aim to exploit this knowledge through the discovery and development of targeted new mechanism antibiotics.”

Shares were up 2% to 38.3p in early afternoon trading.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use